Banner
    Elsevier Announces Title Change And New Editor-In-Chief For Cancer Genetics And Cytogenetics Journal
    By Anna Ohlden | December 6th 2010 04:00 AM | Print | E-mail | Track Comments

    OXFORD, England, December 6, 2010 /PRNewswire/ -- Elsevier, the world's leading publisher of scientific, technical and medical information, announced today that its highly respected Cancer Genetics and Cytogenetics journal is changing its title to Cancer Genetics and has named Dr. Jaclyn A. Biegel as editor-in-chief.

    The changes reflect broader aims and scope for the journal, with a new focus on diagnostic applications as well as the genetic predisposition of cancer, and mark an important move by Elsevier to provide the STM community with a wider variety of original, clinically relevant information for the diagnosis, prognosis and risk evaluation of cancer patients and a greater understanding of how altered gene regulation will ultimately lead to new, targeted therapies for treatment. The first issue of Cancer Genetics will be published in January 2011, with a new cover and interior design.

    Journal Editor-in-Chief Dr. Jaclyn A. Biegel, said, "In addition to papers on the cellular, genetic and molecular aspects of cancer, I look forward to publishing a greater number of articles in the areas of genetic predisposition to cancer, personalized medicine, and new diagnostic approaches. We [also] welcome the submission of classical cytogenetic reports."

    "This is an extraordinary time to work in the field of cancer genetics, as we continue to elucidate the genetic etiology of the many different diseases we call cancer, and enter the era of personalized medicine. In the coming years, we hope to address all of these aspects of cancer research, from gene discovery to risk assessment and treatment, in Cancer Genetics," she added.

    Editor-in-Chief Dr. Jaclyn A. Biegel is the Director of the Cancer Cytogenetics Laboratory at the Children's Hospital of Philadelphia and a Professor of Pediatrics at the University of Pennsylvania School of Medicine. Her clinical expertise is in the diagnosis of pediatric leukemia and solid tumors, and her research expertise is in the genetics of pediatric brain tumors and rhabdoid tumors.

    About Cancer Genetics

    Cancer Genetics (http://www.cancergeneticsjournal.org/), formerly Cancer Genetics and Cytogenetics, is published 12 times a year. It has been published continuously since 1979, a time when cancer cytogenetics was just emerging as a discipline, and investigators in pathology, oncology and genetics were only beginning to assess the genetic basis for hematologic malignancies and solid tumors.

    About Elsevier

    Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell ( http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com/), SciVerse Scopus (http://www.scopus.com/home.url), Reaxys (https://www.reaxys.com/info/), MD Consult (http://www.mdconsult.com/php/229216853-2/homepage) and Nursing Consult (http://www.nursingconsult.com/php/229216862-2/home.html), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review ( http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively.

    A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC ( http://www.reedelsevier.com/Pages/Home.aspx), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact Mustak Kothia +44(0)20-7424-4404 m.kothia@elsevier.com

    SOURCE: Elsevier

    CONTACT: Media Contact: Mustak Kothia, +44(0)20-7424-4404,m.kothia@elsevier.com